To see the other types of publications on this topic, follow the link: Payment institution.
Journal articles on the topic 'Payment institution'
Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles
Consult the top 50 journal articles for your research on the topic 'Payment institution.'
Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.
You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.
Browse journal articles on a wide variety of disciplines and organise your bibliography correctly.
1
Dostov, Victor L., Pavel M. Shust, and Pavel V. Pimenov. "Prospects for the Development of Payment Institutions in Russia." Financial Journal 13, no. 3 (June 2021): 8–26. http://dx.doi.org/10.31107/2075-1990-2021-3-8-26.
Full textAbstract:
The current structure of the Russian payment market is almost ten years old—in the summer of 2011,the Federal Law “On the National Payment System” was adopted. This was the start of a “Russian noncash miracle,” a fantastic increase of non-cash payments in retail turnover. Having solved numerous problems, the new market structure today also needs to be updated. During this decade, the range of challenges faced by the industry and the regulator has changed significantly: those are unbalanced competition, the presence of types of companies with similar functionality on the market, complex licensing procedures, and so on. This article aims to consider a new perspective of market transformation based on the introduction of payment institution into the Russian system. The article analyzes the current and future types of payments; examines in detail the structure of the Russian payment market, its advantages and disadvantages; and describes the payment institution, identifying the risks and prospects of its introduction into Russian banking practice. The authors suggest the feasibility of introducing payment institutions as a more functional version of the payment agents operating in Russia to simplify the complex structure of payment service providers. Payment institutions should become conduits for new payment services (such as PISP and AISP). In addition, payment institutions should be supervised by the regulator. At the same time, the introduction of a new type of companies should not put existing players at a disadvantage. Therefore, existing credit institutions and payment agents should have the ability to easily change their status and transform into payment institutions and back again.
2
Abdelfadeel, Walaa, Nicklaus Houston, Andrew Star, Arjun Saxena, and William J. Hozack. "CT planning studies for robotic total knee arthroplasty." Bone & Joint Journal 102-B, no. 6_Supple_A (June 2020): 79–84. http://dx.doi.org/10.1302/0301-620x.102b6.bjj-2019-1498.r1.
Full textAbstract:
Aims The aim of this study was to analyze the true costs associated with preoperative CT scans performed for robotic-assisted total knee arthroplasty (RATKA) planning and to determine the value of a formal radiologist’s report of these studies. Methods We reviewed 194 CT reports of 176 sequential patients who underwent primary RATKA by a single surgeon at a suburban teaching hospital. CT radiology reports were reviewed for the presence of incidental findings that might change the management of the patient. Payments for the scans, including the technical and professional components, for 330 patients at two hospitals were also recorded and compared. Results There were 82 incidental findings in 61 CT studies, one of which led to a recommendation for additional testing. Across both institutions, the mean total payment for a preoperative scan was $446 ($8 to $3,870). The mean patient payment was $71 ($0 to $2,690). There was wide variation in payments between the institutions. In Institution A, the mean total payment was $258 ($168 to $264), with a mean patient payment of $57 ($0 to $100). The mean technical payment in this institution was $211 ($8 to $856), while the mean professional payment was $48 ($0 to $66). In Institution B, the mean total payment was $636 ($37 to $3,870), with a mean patient payment of $85 ($0 to $2,690). Conclusion The total cost of a CT scan is low and a minimal part of the overall cost of the RATKA. No incidental findings identified on imaging led to a change in management, suggesting that the professional component could be eliminated to reduce costs. Further studies need to take into account the patient perspective and the wide variation in total costs and patient payments across institutions and insurances. Cite this article: Bone Joint J 2020;102-B(6 Supple A):79–84.
3
Padeli, Padeli, Eduard Hotman Purba, and Bonari Simanjuntak. "Analisa Pembayaran Perkuliahan Dengan Virtual Account Pada Universitas Raharja." CICES 6, no. 1 (February 5, 2020): 59–70. http://dx.doi.org/10.33050/cices.v6i1.878.
Full textAbstract:
In the academic world, every educational institution must have a tuition payment system, and with the rapid technological advances nowadays, educational institutions are required to create systems that are effective and efficient and relevant to current technology which will make it superior in competition within the scope of relevant agencies. At Raharja University, lecture payments still use a conventional system where transfer students and campus staff check which is considered less efficient. In this study, the writer uses a SWOT analysis between the virtual account payment system and the running system. The purpose of this study is to recommend the use of a Virtual Account in the payment of lectures at Raharja University. This research is expected to be a problem solving alternative that makes it easier for students to make financial payments, as well as facilitate campus monitoring of campus payments.
4
Doktoralina, Caturida Meiwanto, Zakaria Bahari, and Sakinatul Raadiyah Abdullah. "Mobilisation of Income Zakat Payment In Indonesia." IKONOMIKA 3, no. 2 (January 30, 2019): 189–204. http://dx.doi.org/10.24042/febi.v3i2.3659.
Full textAbstract:
The objectives of the study establish a conceptual framework to strengthen institutions that support the mobilisation of paying zakat and to identify the concept of the cultural factor of mutual assistance in paying zakat. This is Important because the institution of zakat has implemented the collection of zakat. Meanwhile, the culture of mutual assistance in Indonesia can be a power of zakat payment mobilisation to gain the blessings of Allah SWT. This paper presents the factors of determining mobilisation of zakat payments, e.g., are awareness, willingness to donate, confidence in collection and distribution with the latest development of technology. The implication of this study will help mobilise the payment of income zakat in Zakat Institutions. This study uses the documentation analysis method. Factors affecting mobilisation are awareness, willingness to donate, confidence in collection and distribution with the latest development of technology to help mobilise the payment of income zakat in Zakat Institutions. Keywords : Collection, Mobilisation, Payment, Sincerity, Zakat
5
Sravani, B., Dr S. Pradeep, A. Damodar, and K. Kumar Swamy. "Compact Spiral Asymmetric encryption Distributed Ledger –Secured and authentication Mobile Payment System in Higher Institutions." Journal of University of Shanghai for Science and Technology 23, no. 08 (August 17, 2021): 567–82. http://dx.doi.org/10.51201/jusst/21/08427.
Full textAbstract:
Looking at the higher learning institutions, there is no question that the current methods for paying student fees are inefficient, inconvenient, and wasteful of time. In addition, the rise in the number of students studying in higher learning institutions has led to long frustrating queues and overcrowding in most financial institutions during payment of student fees. This paper sought to design and implement a secure block chain-based payment system for higher learning institutions in developing countries. Students are to use the proposed payment system to pay tuition fees and other student fees to their respective higher educational institution. In addition, students are to use the proposed payment to pay for goods and services provided by the institution and other merchants in the institution’s premises. In this study, object oriented software development methodology was used to implement the proposed payment system. The proposed system consists of a mobile e-wallet, RESTful API, and blockchain as the core component of the API.
6
Vavilova, Ekaterina. "On some peculiarities and problems of legal regulation of payments without a bank account." Право и политика, no. 4 (April 2020): 34–41. http://dx.doi.org/10.7256/2454-0706.2020.4.32263.
Full textAbstract:
Due to the extensive changes introduced into the Civil Code of the Russian Federation in 2017, which affected the area of electronic payments, it is relevant to examine the problem and peculiarities of legal regulation of their separate type – payments without a bank account. The subject of this research is legislation of the Russian Federation, case law and doctrine in the area of establishment and development of legal regulation of payments on behalf of private entities without opening a bank account. The object of this research is the public relations emerging in the sphere of legal regulation of payments by payment orders. Analysis is conducted on correlation between payment orders and payments without opening a bank account. The article also examines the grounds for refusal by credit institutions to accept a payment order. The conclusion is made on the existence of discrepancies in understanding of particular grounds for refusal by credit institution to accept payer’s order on transferring funds to a recipient. The formulated conclusions are supported by the law enforcement practice that does not contain the exhaustive list of reasons for refusal. Therefore, the article offers an original interpretation of the Paragraph 2 of Section 2 of the Article 864 of the Civil Code of the Russian Federation stipulating the reasons for refusal to accept payment order for execution.
7
Inoue, Kosuke, Daniel M. Blumenthal, David Elashoff, and Yusuke Tsugawa. "Association between physician characteristics and payments from industry in 2015–2017: observational study." BMJ Open 9, no. 9 (September 2019): e031010. http://dx.doi.org/10.1136/bmjopen-2019-031010.
Full textAbstract:
ObjectiveTo investigate the association between physician characteristics and the value of industry payments.DesignObservational study.Setting and participantsUsing the 2015–2017 Open Payments reports of industry payments linked to the Physician Compare database, we examined the association between physician characteristics (physician sex, years in practice, medical school attended and specialty) and the industry payment value, adjusting for other physician characteristic and institution fixed effects (effectively comparing physicians practicing at the same institution).Main outcome measuresOur primary outcome was the value of total industry payments to physicians including (1) general payments (all forms of payments other than those classified for research purpose, eg, consulting fees, food, beverage), (2) research payments (payments for research endeavours under a written contract or protocol) and (3) ownership interests (eg, stock or stock options, bonds). We also investigated each category of payment separately.ResultsOf 544 264 physicians treating Medicare beneficiaries, a total of $5.8 billion in industry payments were made to 365 801 physicians during 2015–2017. The top 5% of physicians, by cumulative payments, accounted for 91% of industry payments. Within the same institution, male physicians, physicians with 21–30 years in practice and physicians who attended top 50 US medical schools (based on the research ranking) received higher industry payments. Across specialties, orthopaedic surgeons, neurosurgeons and endocrinologists received the highest payments. When we investigated individual types of payment, we found that orthopaedic surgeons received the highest general payments; haematologists/oncologists were the most likely to receive research payments and surgeons were the most likely to receive ownership interests compared with other types of physicians.ConclusionsIndustry payments to physicians were highly concentrated among a small number of physicians. Male sex, longer length of time in clinical practice, graduated from a top-ranked US medical school and practicing certain specialties, were independently associated with higher industry payments.
8
Babin, Igor. "Self-taxation of the population as an institution of financial law." Law Review of Kyiv University of Law, no. 1 (April 15, 2020): 140–43. http://dx.doi.org/10.36695/2219-5521.1.2020.27.
Full textAbstract:
The article reveals the features of self-taxation of the population as an institution of financial law. There is no consensus among national and foreign scholars on the understanding of the nature, place and role of self-taxation in the system of profitable sources of territorial communities. For the most part, self-taxation is considered to be an institution of a tax nature, compulsory non-tax payment, charitable contributions, local borrowing. The problem is also caused by the fact that today in Ukraine there is practically no legislative regulation of this financially legal institute.
The procedure for establishing and entering, the basis for collection and collection depends on the correct determination of the place of each type of payment in the system of revenue of public entities, and in particular in the system of obligatory payments.
Although self-taxation and taxes are inherent in a number of common features (public nature, individual non-gratuity, mandatory payment), these payments cannot be equated. First, self-taxation differs from the taxes by target character. Secondly, self-taxation is characterized by its own form of legalization - holding a general meeting or a local referendum, while for taxes such forms of direct democracy are explicitly prohibited by law. In the foreign scientific literature, based on this peculiarity of self-taxation, it is often called the instrument of direct democracy and the people's financial initiative. Third, self-taxation is different from taxes by the entity of imposed. The subject by imposed of local taxation is the representative body of local self-government (local council), and self-taxation is directly the residents of the respective territorial community. Fourth, self-taxation, unlike taxes, is inherently voluntary in nature. At a general meeting or local referendum, residents of a territorial community voluntarily agree to introduce self-taxation, its size, payment procedure, purpose of using the funds raised, or vice versa, but these issues are not discussed with taxpayers.
It is argued that self-taxation is an independent, non-taxable type of payment that is used to resolve issues of local importance, the size and order of introduction and use are set independently by the population at a general meeting or local referendum. Introducing self-taxation is essential for the development of territorial communities. Self-taxation allows territorial communities to receive additional funds, increase civic activity of residents, and increase the level of responsibility of local self-government bodies.
9
Савченко, С. В. "TO DESCRIBE THE ADDITIONAL ELEMENTS OF MANDATORY PAYMENTS RELATED TO THE RECEIPT OF INHERITANCE AND GIFTS." Juridical science, no. 1(103) (February 19, 2020): 237–43. http://dx.doi.org/10.32844/2222-5374-2020-103-1.28.
Full textAbstract:
The article, based on the analysis of scientific views of scientists and current legislation of Ukraine, provides a description of additional elements of mandatory payments related to inheritance and gifts, including: tax benefits, as well as installments or deferrals in the payment of research payments. It is substantiated that the absence of the institution of installments (deferrals) in the payment of the above tax restricts the rights of low-income persons, as it actually limits the right to receive property free of charge in the form of inheritance or gift.
10
Subagiyo, Dwi Tatak. "Characteristics of Financial Technology as Financing Alternative Capitalization of Medium Small-Medium Enterprises (MSME)." Fiat Justisia: Jurnal Ilmu Hukum 15, no. 2 (April 7, 2021): 133–58. http://dx.doi.org/10.25041/fiatjustisia.v15no2.1933.
Full textAbstract:
Characteristics of Financial Technology as a Financial Institution that uses information technology to provide financial solutions by prioritizing compliance with the principles of prudence and risk management. The characteristics of Financial Technology institutions are getting a loan quickly; Makes Payment Easier; Make Loan Payments without Additional Fees. Peer to Peer Lending (P2P lending) system in providing financial services is done through information technology based. The financial services institution Peer to Peer Lending (P2P Lending) is a financial technology financial institution (Fintech). Financial Technology (Fintech) as a Literacy Source for Financing Micro, Small and Medium Enterprises; Financial Technology (Fintech) As a Facilitator in MSME Development; Financial Tecnology (Fintech) as a driver for Micro, Small and Medium Enterprises to Increase National Financial Inclusion. The Role of the Financial Services Authority (OJK) and the Indonesian Joint Funding Fintech Association (AFPI) As Regulations and Oversight of Financial Technology Institutions (Fintech) in Indonesia.
11
Ma'fiyah, Ma'fiyah, Sheila Ardilla Yughi, and Taufik Awaludin. "Preferensi Muzakki Dalam Memilih Membayar Zakat di Lembaga Zakat Formal." AL-FALAH : Journal of Islamic Economics 3, no. 2 (December 28, 2018): 41. http://dx.doi.org/10.29240/alfalah.v3i2.535.
Full textAbstract:
This study aims to identify the dominant factors that influence muzakki in choosing to pay zakat to formal zakat institutions in aspects of individual and institutional perspectives and provide recommendations related to efforts to increase the collection of zakat funds from the community. The research method used is descriptive, factor and mean analysis. Descriptive analysis was used to explain the demographics of respondents while factor analysis and mean analysis were used to obtain the dominant factors affecting muzakki in paying zakat to the Formal Zakat Institution. The results of the study get in the aspect of individual perspective that predominantly influence muzakki paying zakat to formal zakat institutions sequentially is the knowledge of zakat, faith and religiosity as well as awareness and trust while in the perspective of institutional perspectives are management credibility, institutional credibility, service quality and socialization. The advice given is formal institution zakat amil must professionally manage the institution and have standard operating procedures especially related to the procedure of receiving zakat and commitment to implement it properly. In addition, zakat institutions must inform the general profile of the institution and report on zakat funds regularly. Zakat institutions also have the best online payment facilities.
12
Zhong, Minghua, and Hong Wu. "Research on the Development of Mobile Payment Industry Chain in China." Journal of Computational and Theoretical Nanoscience 14, no. 1 (January 1, 2017): 221–24. http://dx.doi.org/10.1166/jctn.2017.6151.
Full textAbstract:
The rapid development of mobile payment business makes the financial institution, the telecom carrier and the third party payment company to compete to purse the mobile payment market. However, the operation model of mobile payment market is disordered, it affects the development of mobile payment business. Mobile payment main bodies develop quickly. Who will dominate the market, the relationships among them is whether cooperation or competition, how to define the values of the financial institution, the telecom carrier and the third party payment company, are the main questions to be explained. This paper mainly researches on the game among the financial institution, the telecom carrier and the third party company. Through building the game model and the analysis, we draw the conclusion that reasonable resource sharing and income distribution mechanism can help to achieve an all-win result in mobile payment market.
13
Wei, Mu Hua, and Shou Lian Tang. "Evolutionary Game Analysis of the Cooperation Motives of Mobile Operators and Financial Institutions in the Near Field Communication Mobile Payment Industry." Applied Mechanics and Materials 496-500 (January 2014): 2784–87. http://dx.doi.org/10.4028/www.scientific.net/amm.496-500.2784.
Full textAbstract:
Mobile operators and financial institutions are the two major participants in the near field communication (NFC) payment service industry. They provide this service in four different operation modes: mobile operator-financial institution cooperation mode, mobile operators leading mode, financial institutions leading mode, and independent operating mode. The relationship between these two groups is complex because it includes both competition and cooperation. This paper sets up an evolutionary game model to study this special relationship and analyzes the cooperation motives of mobile operators and financial institutions in the NFC mobile payment industry.
14
Pendiuc, Tudor, and Elena Carmen Lis. "PERCEPTIONS OF EXECUTIVE PAYMENT ABUSE IN PUBLIC INSTITUTIONS." Problems of Management in the 21st Century 7, no. 1 (July 15, 2013): 39–49. http://dx.doi.org/10.33225/pmc/13.07.39.
Full textAbstract:
In the aftermath of the financial crisis, executive compensation abuse has been deeply criticized. Thus, the actuality of research is undeniable. The article highlights the importance of learning from other institutions’ past and present executive compensation abuse experiences by presenting the participants’ shared experiences (having to do with executive compensation abuse) and by studying how participants perceive executive compensation abuse. The main objective of this research lies in exploring participants’ shared experiences concerning executive compensation abuse, as well as their perceptions, discrepancies and unsolved questions – presented within an ample, interconnected qualitative and quantitative methodological approach. A sample of 20 individuals was chosen for the triangulation method. From the resultant triangulation six new themes derive from the interview/questionnaire questions specifically referring to executive payment abuse namely: (a) ethics means distinguishing between right and wrong, (b) perspectives of ethical behaviour, (c) types of executive payment abuse, (d) the participant’s perceptions of institution and colleagues. Key words: executive compensation abuse, leader, public institution, perception.
15
Chentsov, A. Y. "The Impact of Digital Technologies on the Development of Payment Services." Digital Transformation, no. 3 (October 14, 2020): 51–57. http://dx.doi.org/10.38086/2522-9613-2020-3-51-57.
Full textAbstract:
The article reveals the system of functioning of payment services as a financial institution, the emergence and development of which is due to scientific and technical progress at the present stage of development and considering the impact of globalization. This tool occupies an increasingly high share of the financial sphere, but due to the novelty of electronic systems, this topic is currently little studied. The article considers the latest developments that allow you to make instant payments conveniently and safely. The problems and ways of protecting user identification, data privacy and money safety when using electronic payment services are investigated. The study revealed that, along with innovative global developments, to strengthen the electronic payment system, it is necessary to implement common international standards for combating cybercrime.
16
Ahadi, Ahmad Husna, and Effiyaldi Effiyaldi. "ANALISIS DAN PERANCANGAN SISTEM INFORMASI ADMINISTRASI PEMBAYARAN BIAYA PENDIDIKAN BERBASIS WEB DAN SMS GATEWAY PADA PONDOK PESANTREN NURUL IMAN MUARO SEBAPO." Jurnal Manajemen Sistem Informasi 4, no. 2 (June 24, 2019): 159. http://dx.doi.org/10.33998/jurnalmanajemensisteminformasi.2019.4.2.621.
Full textAbstract:
Pondok Pesantren Nurul Iman is a religious education institution that has a number of santri as 621people. In the administrative activities of the payment education fees at Pondok Pesantren Nurul Imanstill use manual recording system that experienced various obstacles such as the length of time required toget information on payment of education fee and often the information is not up to the parents of thesantri. Therefore, need a tool in the form of Information Administration System Payments Education Feethat work in computerized, so that can be a solution of the problem. In this research, system design usingUML modeling that produce use case diagram, activity diagram and class diagram. The results of thisresearch is a prototype of the Information System Administration Payment Education Fees based web andSMS Gateway in the hope to help overcome the problems that occur
17
Thanapal, Karthikeya, Dhiraj Mehta, Karthik Mudaliar, and Bushra Shaikh. "Online Payment Using Blockchain." ITM Web of Conferences 32 (2020): 03007. http://dx.doi.org/10.1051/itmconf/20203203007.
Full textAbstract:
Increasing list of records is with blockchain where each record is linked with the help of cryptography. Every block in the chain contains timestamp, transaction details and hash of a previous block, hash is cryptographic hash. This is a secured system, which we plan to replace the current online payment system. A current online payment gateway is prone to hackers where the attacker can tamper into the network, thus creating money loss. And not only this but also the transaction has to go through multiple payment systems which consumes time, also creating a risk of transaction getting failed. So, our system would be using blockchain that allows online transactions which would allow online payments to be sent directly from one party to another without going through a financial institution and in a secured way. This system allows online transactions between two parties based on cryptographic proof without relying and trusting for a third party. To record transactions, we use proof of work algorithm which makes computationally impractical for an attacker to change. Digital signatures provide part of the solution for ensuring the security and integrity of the data that is recorded onto a blockchain.
18
KOLOHOIDA, Oleksandra V., Iryna V. LUKACH, Valeriia V. POIEDYNOK, and Volodymyr I. BOBRYK. "The Settlement Infrastructure of Ukrainian Stock Market: State and Directions for Reform." Journal of Advanced Research in Law and Economics 10, no. 2 (March 31, 2020): 565. http://dx.doi.org/10.14505//jarle.v10.2(40).17.
Full textAbstract:
The research defines the concepts of clearing and clearing activity. It explores the models of the clearing institutions’ organizational structure in EU countries. It also outlines the directions for the settlement and clearing infrastructure reform based on the diversification of the settlement and clearing functions. It should ensure the integrity of the stock market, the reduction of risks, the creation of an efficient and transparent system for the execution of transactions with securities; reduction of expenses of market participants; acceleration of payment terms for operations with securities and process of registration of property rights; differentiation of responsibility at different stages of performance of transactions. The author has defined the legal status of the Financial Settlements Center as a banking institution with a special legal personality of the conducting monetary settlements under transactions concerning securities and other financial instruments, made on the stock exchange and outside the stock exchange, if payments are made according to the principle of ‘supply against payment’. The study shows the need for the universal model of settlements to serve all the exchange markets. We offer to demonopolize the market of clearing services and to provide access for international clearing institutions. We also suggest transferring the settlement function to the Central Depositary and the clearing function – to clearing institutions.
19
Sahabat, Imaduddin, Tumpak Silalahi, Ratih Indrastuti, and Marizsa Herlina. "The interbank payment network and financial system stability." Studies in Economics and Finance 37, no. 1 (September 6, 2019): 1–17. http://dx.doi.org/10.1108/sef-10-2018-0310.
Full textAbstract:
Purpose The financial turbulence resulting from the global financial crisis sparked the interest in improving understanding of financial risks. The transmission of financial institution failures can be determined from the prevailing network structures between banks. The purpose of this study is to identify relationship between payment system network characteristics and financial system condition. Design/methodology/approach The characteristics of the interbank network structure in the payment system are identified using a graph theory and the relationship between the network characteristics of interbank transactions in the payment system and financial system stability is examined using a vector auto regression model. Findings This study shows that the connectedness of large-value payment transaction is more segmented compared to that of retail value payments. A significant relationship is observed between the characteristics of the network and the large-value payment transactions. Research limitations/implications This study found the connectedness of large-value transactions is more segmented when compared to retail-value transactions. It also shows a causal effect of the network characteristic on the financial system stability. Originality/value Unlike existing studies, this study considers both the connectedness in large-value transactions and retail-value transactions.
20
Lessy, Zulkipli. "TREND CIVITAS AKADEMIKA UIN SUNAN KALIJAGA DALAM MEMBAYAR ZAKAT." Al-Maslahah Jurnal Ilmu Syariah 12, no. 2 (January 19, 2017): 367. http://dx.doi.org/10.24260/almaslahah.v12i2.400.
Full textAbstract:
Empowerment of the poor is a long run program. Modern zakat institution is one of
the zakat managements to have long run programs than the mosque takmir. As
academicians, lectures and professors at UIN Sunan Kalijaga knew the existence and
performance of modern zakat management. The research was aimed to explore zakat
payment trends conducted by the lecturers and professors. First, the attitude of those
lecturers and professors in giving their zakat either fitrah or maal; whether the
payment was done by giving direct cash to zakat institutions or to mustahiq and the
mosque takmir. Second, reasons that lay beyond choosing the payment methods. The
results indicated the respondents tended to conserve the traditional method in giving
zakat to the poor and the mosque. From 95 respondents surveyed, fifty five
respondents paid their zakat fitrah and maal directly to individuals because they
witness living poor individuals in their neighboorhood, and fourty respondents chose
the modern method. And, from 95 respondents, twelve of the did not trust zakat
institutions. Therefore, they paid their zakat directly to the poor.
Keywords: Trend, zakat, institution, mosque, individual.
Kata-kata kunci: trend, zakat, lembaga, masjid, individu
21
Boddapati, Venkat, Michael C. Fu, Benedict U. Nwachukwu, Anil S. Ranawat, Wilson Y. Zhen, and Joshua S. Dines. "Accuracy Between AJSM Author-Reported Disclosures and the Centers for Medicare and Medicaid Services Open Payments Database." American Journal of Sports Medicine 46, no. 4 (January 30, 2018): 969–76. http://dx.doi.org/10.1177/0363546517750124.
Full textAbstract:
Background: Inaccurate disclosures of physician and industry relationships in scientific reporting may create an asymmetry of information by hiding potential biases. The accuracy of conflict of interest disclosure in sports medicine research is unknown. Purpose: To compare author financial disclosures in published articles in 2016 in the American Journal of Sports Medicine ( AJSM) with the Centers for Medicare and Medicaid Services’ Open Payments Database (OPD) to determine the percentage of payments values and percentage of eligible authors with discrepancies. Study Design: Cross-sectional study; no level of evidence (nonclinical). Methods: All articles published in 2016 in AJSM were screened to identify eligible authors. On the basis of OPD reporting, physician authors affiliated with a US institution were included. Stated disclosures in AJSM publications for these authors were identified and compared with industry-reported payments on OPD. Results: A total of 434 authors were included in this study. Mean and median total payments per author per year were $76,941 and $1692, respectively. The most commonly received payment was for food and beverage (81.3% of authors), followed by travel and lodging (45.4%) and consulting (31.8%). Authors with higher total payments were less likely to be discrepant in their reporting—notably, authors earning >$500,000 had 16.1% of payment values with discrepancy, as opposed to 85.3% for those earning <$10,000 ( P < .001). First authors had a lower percentage of payment values with discrepancy (13.8%) versus middle authors (31.9%, P = .001). Finally, men had a lower percentage of payment values with discrepancy (418 authors, 22.3% of payment values with discrepancy) as compared with women (16 authors, 95.3%; P < .001). Regarding industry payments specifically requested on the AJSM disclosure form for authors (royalties, consulting, research payments, and ownership and investments), only 25.3% of authors had a discrepancy in these payment categories in aggregate. Conclusion: Discrepancies exist between disclosures reported by authors publishing in AJSM and what is reported in the OPD. Authors receiving lower total payments, middle authors, and women are more likely to have disclosure discrepancies. Additionally, industry research funding support and ownership interest are most likely to go unreported. However, this study did not assess whether authors with industry payments preferentially published studies pertaining to products from companies from which they received funding. As national registries such as the OPD are increasingly utilized, physicians may benefit from referencing such databases before submitting conflict of interest disclosures.
22
Butova, Valentina Gavrilovna, A. E. Olesov, M. V. Zuev, K. V. Umarova, A. Yu Zherebtsov, and V. A. Peshkov. "THE MONITORING OF DENTAL ORGANIZATION’S MEDICAL WORKERS COMPETENCES ACCORDING TO THE NEW SYSTEM OF WAGE PAYMENTS." Russian Journal of Dentistry 21, no. 4 (August 15, 2017): 211–16. http://dx.doi.org/10.18821/1728-2802-2017-21-4-211-216.
Full textAbstract:
Using the method of empirical anonymous sociological research the competence of 630 dentists and health care institutions managers according to the new system of wage payments (NSWP) was studied. On the 7 questions asked, containing about 6138 possible answers from all the respondents 2253 correct answers were retrieved which represents 36,7% of all responses. Found data shows that only every third dental clinic specialist has the competence in NSWP while the majority 63, 3% are not quite oriented in the NSWP. One of the main problems of the NSWP integration is lack of understanding of basic principles and specific criteria of work quality assessment from health care institutions employees thus nullifies the potentially high impact of its introduction. Raise of the transparency of wage payment system will cause significant personnel motivation improvement in achieving qualitative and quantitative labor values that the authority has laid for the organization that are tied to the work goals of the institution itself and the health care system as a whole. Medical institution administration system should use new tools for staff competence improvement nowadays. It is necessary to provide professional communication space for colleagues on the questions of NSWP.
23
Dinku, Tirngo. "Financial inclusion in Ethiopia: Using core set of financial inclusion indicators." International Journal of Social Sciences and Humanities Invention 8, no. 03 (March 31, 2021): 6396–404. http://dx.doi.org/10.18535/ijsshi/v8i03.01.
Full textAbstract:
Financial inclusion is the key to inclusive development throughout the world. It is the access to get financial services such as saving, loan, insurance and others easily at an affordable cost, this study aims at evaluating the level of financial inclusion in Ethiopia in comparison with Sub Saharan Africa and low income countries. World Bank group 2017data on financial inclusion is used.The result shows access to have a bank account and account at other financial institution has been realized improvement to the year, where as it is far below the Sub Saharan African average. The major reason for not having a bank account or account at financial institutions in Ethiopia areinsufficient fund and financial institutions are too far away, while religious reasons and lack of trust on financial institutions are the least. No one pays utility bill digitally, the use of digital payment is very poor in Ethiopia; only three out of hundred individuals in Ethiopia used an account to receive government payments.
24
Agus, Dede Agus. "PERLINDUNGAN PEMBAYARAN UPAH PEKERJA PASCA PUTUSAN MAHKAMAH KONSTITUSI NO. 100/PUU-X/2012 TENTANG UJI MATERIAL UU NO. 13 TAHUN 2003 TENTANG KETENAGAKERJAAN." Jurnal Hukum Samudra Keadilan 15, no. 1 (June 5, 2020): 1–16. http://dx.doi.org/10.33059/jhsk.v15i1.1819.
Full textAbstract:
Employers may be protected from the obligation to pay wages and any payments arising from employment if it has expired two year since the inception of the right. This is unfair to workers (harm), then judicial review an article 96 of Law No.13 of 2003 on Manpower to Constitution by the Constitutional Court Decision Number 100 / PUU-X / 2012. Therefore, this paper is aimed to discuss the protection of wage payment of workers post-judicial review. This research method, normative juridical based on the secondary data and the statute approach, conceptual approach, case approach and qualitative descriptive analysis. The results showed that the Post-Decision of the Constitutional Court payment of wages of workers has been protected, this is no expiry in the payment of wages and other benefits. The Constitutional Court declares that Article 96 of Law No.13 of 2003 is contradictory to the Constitution, and has no binding force. The Constitutional Court's verdict provides legal certainty that wages and any payments arising from employment relationships may at any time be prosecuted if they have not been fulfilled, but on the other hand it creates legal uncertainty, since the expiration institution is created by law in the context of legal certainty.
25
Muthohar, Ahmad Mifdlol. "Analysis of Influence of Intrinsic Aspect, Demography Aspect and Service of Zakat Institution toward Zakat Payment to Zakat Institution." INFERENSI: Jurnal Penelitian Sosial Keagamaan 13, no. 1 (July 20, 2019): 25–50. http://dx.doi.org/10.18326/infsl3.v13i1.25-50.
Full textAbstract:
This study aimed to determine the concept of the blessing of zakat and the muzaki’s perception about the blessings and to find internal factors that affected the muzaki in issuing zakat to zakat institutions. These factors were the service of zakat institutions, muzaki’s religiosity, feeling blessed, gender, education level, and occupation, whether all of which affected the propensity of their choice in issuing zakat to zakat institutions. Sampling used purposive random sampling. For data analysis tools, this study used multiple regression analysis with tobit models. The findings in this study showed that the feeling of blessing by issuing zakat and occupational factors did not significantly influence the preferences of muzaki to issue zakat to certain zakat institutions. For the service of zakat institution, gender, and education level, they significantly and positively affected the preferences to issue zakat to zakat institutions. The variable of muzaki’s religiosity negatively affected the trend in the choice of muzaki to issue zakat to zakat institutions significantly.
26
Polese, Abel, Tetiana Stepurko, Svitlana Oksamytna, Tanel Kerikmae, Archil Chochia, and Olena Levenets. "Informality and Ukrainian higher educational institutions: Happy together?" Policy Futures in Education 16, no. 4 (March 13, 2018): 482–500. http://dx.doi.org/10.1177/1478210318758812.
Full textAbstract:
In post-socialist spaces, informal payments in educational institutions have often been at the centre of anti-corruption campaigns. A direct consequence, so far, has been that reforms in the public sector have largely been based on attempts to eradicate, or at least minimize, the phenomenon of informal payments. Ukraine is no exception. According to several independent surveys, educational institutions are second only to health care providers for the number of informal transactions recorded. While more than two in three of Ukrainians claim to have engaged with informal exchanges in the past 12 months, almost half of them has made an informal payment in an educational institution, be this a university or a school. The goal of this paper is two-fold. First, we explore the nature and relevance of the phenomenon of informal payments in the educational sector. We rely for this on quantitative studies showing how widespread informal payments are. Second, we provide an alternative explanation on informal payments by suggesting that they have an ambiguous function: while often regarded as a legacy of the socialist period, they can also be seen as a way to cope with an ineffective system that is mostly based on informal rules. By doing this we will provide some recommendations on how anti-corruption policies, and in general reforms aimed at decreasing the amount of informal payments in the country, could be improved.
27
Gangat, Naseema, Brady Lee Stein, Christian Marinaccio, Ronan Swords, Justin M. Watts, Sandeep Gurbuxani, Olga Frankfurt, et al. "Alisertib (MLN8237), an Oral Selective Inhibitor of Aurora Kinase a, Has Clinical Activity and Restores GATA1 Expression in Patients with Myelofibrosis." Blood 132, Supplement 1 (November 29, 2018): 688. http://dx.doi.org/10.1182/blood-2018-99-110381.
Full textAbstract:
Abstract Background: The selective AURKA inhibitor alisertib (MLN8237) exhibits disease modifying activity in murine models of myelofibrosis by eradicating atypical megakaryocytes resulting in reduction of marrow fibrosis (Nat Med 2015). Here, we present long term follow-up results from the investigator initiated pilot study of alisertib in patients with myelofibrosis (clinical trials.gov Identifier NCT 02530619). Methods: 24 patients with DIPSS intermediate 1, intermediate-2, or high risk myelofibrosis who were in need of therapy, refractory/intolerant or unlikely to respond to JAK inhibitors with neutrophil count ≥ 1 x109/L, and platelet count ≥ 50 x109/L, received alisertib (provided by Millennium Pharmaceuticals Inc) at a dose of 50 mg twice daily for one week every 21 days. Toxicity assessment was performed by the standard common terminology criteria (Version 4.0). Response was assessed by the international working group for myelofibrosis research and treatment (IWGMRT) criteria. Correlative studies included assessments of JAK2V617F, CALR, and MPL mutant allele burden, degree of fibrosis and GATA1 expression in bone marrow samples obtained pre and post therapy. Results: We enrolled 17 patients with primary myelofibrosis, 4 with post essential thrombocythemia myelofibrosis and 3 with post polycythemia vera myelofibrosis. Median age was 72 years with 66% males. 79% of patients were DIPSS intermediate risk, and the remainder were high risk with 15 patients (62.5%) having received prior JAK inhibitor therapy. Driver mutational status was as follows; 58% JAK2V617F, 29% CALR, and 13% MPL mutated. At study entry, 54% of patients demonstrated palpable splenomegaly ≥ 5 cm below the left costal margin, 54% were transfusion dependent with all patients experiencing constitutional symptoms. At the time of data cut-off, patients received a median of 7.5 cycles (range; 1-29 cycles) of therapy. The 7 patients presently on study have received a median of 23 cycles (range; 8-29 cycles). Reasons for treatment discontinuation included progressive disease/lack of response in 11 (65%) patients, toxicity in 4 (24%) patients and refusal of further therapy in 2 (11%) patients.Safety and Efficacy assessments The most common treatment-emergent grade 3/4 adverse events included neutropenia (42%), thrombocytopenia (29%) and anemia (21%), with 4% each experiencing neutropenic fever, diarrhea, vertigo, elevated creatinine and elevated alanine aminotransferase. 22 patients were considered for response evaluation with 4 of 14 patients (29%) with palpable splenomegaly ≥ 5 cm achieving a spleen response, 1 of 13 patients (8%) becoming transfusion independent, and 5 of 22 patients (23%) experiencing symptom response with ≥ 50% reduction in the MPN-SAF total symptom score. However, when response assessment was restricted to 13 patients who had received a minimum of 5 cycles of therapy, spleen responses were observed in 4 of 7 (57%) patients, 1 of 5 (20%) achieved transfusion independence and 5 of 13 (38%) achieved symptom response. All patients presenting with leukocytosis (n=4) and thrombocytosis (n=2) had resolution with therapy. Of the 7 patients presently on study, four patients continue to demonstrate symptom response, two patients with both spleen and symptom response, and another patient with sustained anemia response. Correlative assessments We compared the intensity of staining of GATA1, a factor that is required for maturation, in sequential bone marrow biopsies from six patients at baseline and after a minimum of five cycles and observed a striking increase in the numbers of GATA1-positive megakaryocytes in five of six cases (Figure 1a). In addition, we observed a one grade reduction in marrow fibrosis in 4 of 6 paired samples (Figure 1b). This reduction in fibrosis was accompanied by sustained responses to the drug. Finally, we compared JAK2, MPL or CALR mutant allele burden in eight paired baseline and cycle 5 or 6 samples and observed decreases in 4 of 8 patients (Figure 1c). Conclusions: Alisertib is safe and well tolerated in patients with myelofibrosis with prolonged administration up to 1.7 years. In addition to providing clinical benefit, alisertib restored normal morphology and GATA1 expression in atypical megakaryocytes and reduced marrow fibrosis and mutant allele burdens. These findings demonstrate that AURKA inhibition should be further explored as a therapeutic option in myelofibrosis. Figure 1. Figure 1. Disclosures Swords: AbbVie: Employment. Watts:Jazz Pharma: Consultancy, Speakers Bureau; Takeda: Research Funding. Frankfurt:Celgene, Jazz, Agios: Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; AbbVie: Membership on an entity's Board of Directors or advisory committees. Altman:Cyclacel: Other: payment to the institution to conduct clinical trial work; Epizyme: Other: payment to the institution to conduct clinical trial work; Ariad: Other: payment to the institution to conduct clinical trial work; Bayer: Other: payment to the institution to conduct clinical trial work; Celator: Other: payment to the institution to conduct clinical trial work; FujiFilm: Other: payment to the institution to conduct clinical trial work; Celgene: Membership on an entity's Board of Directors or advisory committees, Other: payment to the institution to conduct clinical trial work; Agios: Other: Payment to the institution to conduct the trial ; Astellas Pharma: Other; Genetech: Other: Payment to the institution to conduct clinical trial work; Syros: Membership on an entity's Board of Directors or advisory committees; Incyte: Other: payment to the institution to conduct clinical trial work; GSK: Other: payment to the institution to conduct clinical trial work; Immune Pharmaceuticals: Membership on an entity's Board of Directors or advisory committees; BMS: Membership on an entity's Board of Directors or advisory committees; Janssen Pharmaceuticals: Membership on an entity's Board of Directors or advisory committees; Boeringer Ingelheim: Other: payment to the institution to conduct clinical trial work; Novartis: Membership on an entity's Board of Directors or advisory committees; Pfizer: Other: payment to the institution to conduct clinical trial work. Rampal:Celgene: Honoraria; Stemline: Research Funding; Incyte: Honoraria, Research Funding; Constellation: Research Funding; Jazz: Consultancy, Honoraria. Giles:Actuate Therapeutics Inc: Employment, Equity Ownership. Crispino:Forma Therapeutics: Research Funding; Scholar Rock: Research Funding.
28
Gunawan, Karebet. "PELAYANAN LEMBAGA ZAKAT UNTUK MENINGKATKAN KEPUASAN MUZAKKI." ZISWAF : Jurnal Zakat dan Wakaf 4, no. 2 (February 18, 2018): 297. http://dx.doi.org/10.21043/ziswaf.v4i2.3047.
Full textAbstract:
Zakat is one of the links of a Muslim identity. Zakat not only benefits the recipients, but can provide enormous benefits to those who issue zakat. Zakat institutions basically in providing services must be transparent and can satisfactory to all parties so that it can lead to loyalty of users. Zakat institutions must work how to create the satisfaction of muzakki so that the funds collected more and more. The payment of zakat through one of zakat institutions is a form of tabligh and at the same time gives an example to other parties to implement the teachings of zakat in an organized manner. In addition, zakat institutions should also improve the quality of service so that with good service the zakat institution users will be more loyal. With loyalty it can cause muzakki more tied with zakat institution.
29
Rahayu, Puji. "Tax Planning Melalui Penerapan Zakat Sebagai Upaya Meminimalisir Beban Pajak Badan (Studi Kasus Pada PT. Wonojati Wijoyo, Kediri)." Ekuilibrium : Jurnal Ilmiah Bidang Ilmu Ekonomi 12, no. 2 (November 7, 2017): 125. http://dx.doi.org/10.24269/ekuilibrium.v12i2.675.
Full textAbstract:
Implementation of tax planning through tax lawdengan exploiting loopholes in tax regulations one of which is exempted from the tax object is the payment of zakat on the amil zakat or amil zakat institutions established or endorsed by the government. Zakat is part of the pillar of Islam is the third pillar. For the Islamic ummah zakat law it must be done.Manajemen company has done tax planning in minimizing the tax burden.How that has been used by companies through depreciation of assets and financing the procurement of goods using leasing or leasing services.Namun companies have never applied zakat payments As a tax savings. The purpose of this study to know the tax planning through the implementation of zakat as an effort to minimize the agency tax burden.Types of data used in this study are qualitative and quantitative data.Data in this study are taken directly in the form of data about corporate organizational structure, employee data, company history and tax planning system that has been applied company. The data analysis technique used in this research is qualitative descriptive by analyzing fiscal reconciliation in order to calculate the Corporate Income Tax by applying the company before applying the tax planning through the payment of zakat, calculating the amount of zakat, calculating the Income Tax after applying the tax planning through zakat payment, Comparing the Income Taxes owed before After applying the tax planning through the payment of zakat.From the research result, it is concluded that the income tax burden payable by the company in 2016 before doing the implementation of tax planning through the payment of zakat amounting to Rp 282.355.625, - while after implementing the zakat of Rp 275.449.750, - the difference of Rp 6.905.875, - And tax payable prior to the fiscal reconciliation of Rp 275,096,375,-. There is a difference of Rp 353,375, - so the researcher recommends to apply zakat payment to amil zalcat or amil zalcat institution which has been legalized by the government because it has been legalized by taxation and paying zakat besides being able to clean the property is also a mandatory command of Allah SWT We carry out according to His word in the Al-Qur'an.
30
BAIAS, Flavius Antoniu, and Stela STOICESCU. "Prestaţia compensatorie în Codul civil român." Analele Universitării din București Drept 2021, no. 2021 (July 2, 2021): 164–79. http://dx.doi.org/10.31178/aubd.2021.12.
Full textAbstract:
This study aims to describe the legal regime of the compensatory payment, with reference to the legislative framework, the sources of inspiration of the regulation, as well as to the current national case-law in this matter, which confirms, by the large number of cases solved after the entry into force of the Civil Code, the social utility of this legal institution. On the basis of the case law examples provided, the authors analyze the legal nature of the compensatory allowance by distinguishing it from similar institutions – the maintenance obligation between ex-spouses or the right to compensation – the conditions to be fulfilled when granting compensatory payment, the criteria used to impose, modify or terminate the obligation, and the substantive and procedural law difficulties of these disputes.
31
Rosyida, Matsna Agustina, Siti Sufaidah, and Tholib Hariono. "SISTEM APLIKASI PEMBAYARAN SISWA MENGGUNAKAN BAHASA PEMROGRAMAN VISUAL BASIC 6.0." SAINTEKBU 10, no. 2 (July 28, 2018): 61–68. http://dx.doi.org/10.32764/saintekbu.v10i2.209.
Full textAbstract:
Madrasah is an educational institution under the auspices of the Education Department which is moving in the field of school services. Madrasahs that are still manual in handling activities such as recording payment transactions and reporting, manual here in the sense that there is no system that is integrated between parts. Manual record-keeping and reporting are irrelevant or out of date with the fast-paced, precise and accurate progress of the times. Therefore the need for a transition from a manual system to a computerized system. The computerized system to be created should be tailored to the needs of the madrasah. In this research, the writer tries to build madrasah payment system with the database so that it becomes better payment system, effective and efficient and help solve problems faced by the institution in Madrasah Aliyah Negeri Kandangan Office Kediri Regency related to the payment system (like reporting and print receipt). In this case, the database will be used is Access, While the programming using Visual Basic 6.0. In this study discussed the test of the program that has been made. It aims to determine the extent to which the exact execution of programs that have been made and did not rule out knowing weaknesses. So it can be concluded that the program created can run correctly and in accordance with what is expected. Whereas with the construction of this Madrasah Payment Application Sistem, problems in making payment data such as reporting and proof of payment (Receipt) can provide convenience for the officers. Also with database utilization, payment data will be saved automatically.
Keywords: Access, Visual Basic 6.0, Student Payout.
32
Foran, James M., Zhuoxin Sun, Elisabeth Paietta, Janis Racevskis, David F. Claxton, Hillard M. Lazarus, Daniel A. Arber, et al. "Minimal Residual Disease (MRD) at Time of Complete Remission Is Commonly Detected in Acute Myeloid Leukemia (AML) Patients Age ≥60 Years and Significantly Impacts Outcome Based on Post-Remission Treatment Strategies: Prospective Analysis of ECOG-ACRIN (E-A) E2906 Phase III Trial." Blood 132, Supplement 1 (November 29, 2018): 437. http://dx.doi.org/10.1182/blood-2018-99-113950.
Full textAbstract:
Abstract Background: The persistence of detectable MRD in complete remission (CR/CRi - CR with incomplete CBC recovery) has been reported to contribute to inferior outcome in younger AML patients (pts) in retrospective studies, however MRD has not been studied prospectively in older adults (age ≥60 yrs) receiving intensive therapy with curative intent. We performed a planned prospective study of MRD status after AML induction therapy in older adults, integrated into the large multicenter ECOG-ACRIN (E-A) E2906 Phase III trial. Methods Eligible patients age ≥60 yrs with AML were randomized 1:1 to receive either 'Standard' 7&3 (Dauno 60mg/m2) induction, with 2 cycles of intermediate dose Ara-C (1.5g/m2 x 12 doses; 6 doses if age ≥70) consolidation (Arm A); or single agent clofarabine (CLO) induction and consolidation (2 cycles) (Arm B). The design and primary clinical results for E2906 (n=727) have been reported previously (Foran et al, ASH #217a, 2015), demonstrating superior overall survival (OS) with standard therapy despite similar CR/CRi rates using stringent criteria, and similar 30-day induction mortality rates. Submission of diagnostic & remission bone marrow or peripheral blood samples was protocol mandated for prospective MRD assessment, and analysis was performed in the central E-A Leukemia Translational Research Lab (LTL) using 6-color multiparameter flow cytometry. MRD-positive (MRD+) was defined as ≥0.1%. LTL flow cytometric analysis was done blinded to treatment arm and outcome of patients. Only pt samples collected within +/-6 days of CR/CRi confirmation were included in this analysis. Statistical analysis was performed using X2 (categories) and Wilcoxon rank sum (continuous) tests to compare baseline patient and disease characteristics. Log-rank tests and multivariate Cox models stratified by treatment arm and adjusted for patient and disease variable (including WBC, cytogenetics, sex, performance status, secondary AML) were used to examine the MRD effect on OS and disease-free survival (DFS, relapse or death). Results The median follow-up is 47.8 months, and 297 of 685 evaluable patients (43.4%) achieved CR/CRi (Standard 44.6%; CLO 42.0%, p=ns). Remission MRD samples were only available for 147 CR/CRi patients (49.5%), owing to variability in sample viability and AML involvement, collection practices and timing of sample collection at individual sites, and patient/physician decision. 58/147 evaluable CR/CRi patients achieved MRD-negative (MRD-) status (Standard 40.7%, CLO 47.9%, p=0.74). Women (56.9% vs. men 43.1%, p=0.003) were more likely to be MRD-, but there was no other significant difference in MRD status stratified by clinical or disease features. MRD+ status at CR/CRi was associated with significantly inferior OS (p=0.031, Figure 1) and also inferior overall DFS (p=0.02); this was most pronounced for DFS after CLO (Arm B, Figure 2) (p=0.005), but not Standard (Arm A) therapy (p=0.41). The impact of MRD+ was confirmed on multivariate analysis using Cox Model Fitting, for OS: OS for All MRD+ pts, HR 1.64 (95% CI 1.00-2.68) (p=0.05); OS for Standard (Arm A) MRD+ pts, HR 1.06 (95% CI 0.51-2.21) (p=0.87); and OS for CLO (Arm B) MRD+ pts, HR 2.30 (95% CI 1.05-5.06) (p=0.04). There was a similar impact for DFS on multivariate analysis using Cox Model Fitting: DFS for All MRD+ pts, HR 1.86 (95% CI 1.16-2.98) (p=0.01); DFS for Standard (Arm A) MRD+ pts, HR 1.15 (95% CI 0.60-2.19) (p=0.67); and DFS for CLO (Arm B) MRD+ pts, HR 3.45 (95% CI 1.47-8.09) (p=0.004). Post-remission therapy was not stratified by MRD in E2906, and 33% of MRD-evaluable pts underwent allogeneic transplantation (no difference in transplant rate for MRD+ vs. MRD-). Conclusions MRD+ ≥0.1% is common (60.5%) after induction therapy in older adults & is significantly associated with inferior OS and DFS in 1st CR/CRi. However we observed excellent outcomes for MRD- pts in first CR/CRi regardless of induction regimen or post-remission therapy used. MRD+ pts in CR/CRi who went on to receive CLO consolidation had significantly poorer outcomes than those who went on to receive intermediate dose Ara-C consolidation. This observation differs strikingly from younger AML, and suggests that intensified Ara-C may abrogate the adverse impact of MRD in older pts in CR. These results strongly support incorporation of centralized MRD at the time of remission into future studies to guide optimal post-remission strategies in older pts with AML. Disclosures Foran: Agios: Research Funding; Xencor, Inc.: Research Funding. Lazarus:Pluristem Ltd.: Consultancy. Altman:Bayer: Other: payment to the institution to conduct clinical trial work; Pfizer: Other: payment to the institution to conduct clinical trial work; Boeringer Ingelheim: Other: payment to the institution to conduct clinical trial work; Epizyme: Other: payment to the institution to conduct clinical trial work; Janssen Pharmaceuticals: Membership on an entity's Board of Directors or advisory committees; Immune Pharmaceuticals: Membership on an entity's Board of Directors or advisory committees; Cyclacel: Other: payment to the institution to conduct clinical trial work; Incyte: Other: payment to the institution to conduct clinical trial work; GSK: Other: payment to the institution to conduct clinical trial work; Agios: Other: Payment to the institution to conduct the trial ; Astellas Pharma: Other; Celgene: Membership on an entity's Board of Directors or advisory committees, Other: payment to the institution to conduct clinical trial work; BMS: Membership on an entity's Board of Directors or advisory committees; Syros: Membership on an entity's Board of Directors or advisory committees; Novartis: Membership on an entity's Board of Directors or advisory committees; Ariad: Other: payment to the institution to conduct clinical trial work; FujiFilm: Other: payment to the institution to conduct clinical trial work; Genetech: Other: Payment to the institution to conduct clinical trial work; Celator: Other: payment to the institution to conduct clinical trial work. Al-Kali:Novartis: Research Funding. Pratz:Millenium/Takeda: Research Funding; Agios: Research Funding; AbbVie: Consultancy, Research Funding; Astellas: Consultancy, Research Funding; Boston Scientific: Consultancy. Powell:Rafael Pharmaceuticals: Membership on an entity's Board of Directors or advisory committees. Tallman:ADC Therapeutics: Research Funding; BioSight: Other: Advisory board; Daiichi-Sankyo: Other: Advisory board; Orsenix: Other: Advisory board; AROG: Research Funding; AbbVie: Research Funding; Cellerant: Research Funding.
33
Park, Jae H., Jeong-Ok Lee, Richard M. Stone, Alan Saven, Jessica K. Altman, Michael R. Grever, Kanti R. Rai, Shreya Vemuri, Omar I. Abdel-Wahab, and Martin S. Tallman. "Acquired Resistance to BRAF Inhibition in Hcl Is Rare and Retreatment with Vemurafenib at Relapse Can Induce High Response Rates: Final Results of a Phase II Trial of Vemurafenib in Relapsed Hcl." Blood 132, Supplement 1 (November 29, 2018): 392. http://dx.doi.org/10.1182/blood-2018-99-119949.
Full textAbstract:
Abstract Background: We have previously reported initial high response rates of the BRAF inhibitor, vemurafenib, in patients (pts) with relapsed or refractory (R/R) hairy cell leukemia (HCL) treated in the United States (Tiacci and Park et al. N Engl J Med 2015). However, follow-up duration of the study was short (median, 11.7 months) and outcome of the pts who relapsed after vemurafenib remains largely unknown. Herein, we report the updated results of 36 pts from the completed clinical trial in the U.S. (NCT01711632) with a longer follow-up duration with analysis on the rates and timing of relapse as well as outcomes after retreatment with vemurafenib. Methods: In the U.S. phase II clinical trial, adult pts with R/R HCL received vemurafenib 960mg bid monotherapy for 3-6 months. Vemurafenib dose reductions were allowed for drug-related adverse events (AEs). During subsequent follow-up, pts with relapsed disease were allowed to be retreated with vemurafenib at doses ranging from 240mg bid to 960mg bid at the discretion of treating physician based on prior tolerability information. The primary objective was to evaluate overall response rates (ORR) of vemurafenib in R/R HCL, as assessed by the rate of complete remission (CR) and partial remission (PR). CR was defined as normalization of any organomegaly and cytopenia with a morphologic absence of hairy cells in the blood and bone marrow (BM). PR was defined as a normalization of cytopenia with ≥50% reduction in organomegaly and BM hairy cells. Patients with normalization of cytopenia without confirmatory BM were classified as complete hematologic remission (CHR). Secondary objectives included assessment of duration of response and efficacy of vemurafenib at retreatment. Results: A total of 36 pts were enrolled to the study; 32 pts completed at least 4 weeks of treatment and are evaluable for response, and 4 pts discontinued therapy before 4 weeks due to toxicity (n=2), infection (n=1) and patient request (n=1). The ORR was 86% (31/36 pts), including 33% CR (12/36) and 53% PR (19/36). With a median follow-up of 24 months (range, 1-64 months), 18 pts (50%) experienced relapse (Figure). The median time to relapse was 19.5 months (range, 8.0-45.7 months). Among the 18 pts with relapse, 13 pts (72%) received retreatment with vemurafenib, 4 pts (22%) received alternative treatments, and 1 pt (6%) received supportive care. Eleven of the 13 pts (85%) retreated with vemurafenib at relapse achieved PR/CHR and 1 pt developed acquired resistance to vemurafenib with KRAS mutation. Vemurafenib retreatment was well-tolerated but the majority (62%) of pts received a reduce dose of 240mg bid (n=5) or 480mg bid (n=3) with a median duration of therapy of 7 months (range, 1.5-39 months). The most common drug-related AEs during vemurafenib retreatment were similar to the initial treatment and included arthralgia (38%) and rash (23%), all of which were grade 1 or 2, except one case of grade 3 rash. During the entire follow-up period of all pts, cutaneous squamous cell carcinomas (SCC) developed in 5 pts (14%) and cutaneous basal cell carcinoma (BCC) developed in 1 pt (3%), 4 of whom had a prior history of SCC (n=1), BCC (n=1), BCC/melanoma in situ (n=1) and actinic keratosis (n=1). All these cases were managed by simple excision. Conclusion: With a longer follow-up duration of up to 64 months, we confirm the high response rates with vemurafenib monotherapy in pts with R/R HCL and a favorable safety profile. While relapses were common, all cases of relapse retained BRAF V600E mutation and acquired resistance to vemurafenib was rare, observed in only 1 pt with KRAS mutation. Re-treatment with vemurafenib at relapse was highly effective with 85% ORR confirming the retained high sensitivity of HCL to repeated BRAF inhibition. Based on the high anti-tumor efficacy and tolerability of BRAF inhibition with vemurafenib, we are now investigating the combination of vemurafenib and an anti-CD20 antibody, obinutuzumab, as a frontline therapy in a phase II trial in pts with previously untreated HCL (NCT03410875). Figure. Figure. Disclosures Park: AstraZeneca: Consultancy; Juno Therapeutics: Consultancy, Research Funding; Pfizer: Consultancy; Shire: Consultancy; Amgen: Consultancy, Membership on an entity's Board of Directors or advisory committees; Kite Pharma: Consultancy; Novartis: Consultancy; Adaptive Biotechnologies: Consultancy. Altman:Bayer: Other: payment to the institution to conduct clinical trial work; Boeringer Ingelheim: Other: payment to the institution to conduct clinical trial work; Epizyme: Other: payment to the institution to conduct clinical trial work; Incyte: Other: payment to the institution to conduct clinical trial work; Cyclacel: Other: payment to the institution to conduct clinical trial work; Syros: Membership on an entity's Board of Directors or advisory committees; Novartis: Membership on an entity's Board of Directors or advisory committees; Ariad: Other: payment to the institution to conduct clinical trial work; Genetech: Other: Payment to the institution to conduct clinical trial work; Agios: Other: Payment to the institution to conduct the trial ; Astellas Pharma: Other; Celgene: Membership on an entity's Board of Directors or advisory committees, Other: payment to the institution to conduct clinical trial work; FujiFilm: Other: payment to the institution to conduct clinical trial work; Celator: Other: payment to the institution to conduct clinical trial work; Pfizer: Other: payment to the institution to conduct clinical trial work; GSK: Other: payment to the institution to conduct clinical trial work; BMS: Membership on an entity's Board of Directors or advisory committees; Janssen Pharmaceuticals: Membership on an entity's Board of Directors or advisory committees; Immune Pharmaceuticals: Membership on an entity's Board of Directors or advisory committees. Rai:Pharmacyclics: Membership on an entity's Board of Directors or advisory committees; Roche/Genentech: Membership on an entity's Board of Directors or advisory committees; Cellectis: Membership on an entity's Board of Directors or advisory committees. Tallman:Daiichi-Sankyo: Other: Advisory board; AROG: Research Funding; AbbVie: Research Funding; Cellerant: Research Funding; BioSight: Other: Advisory board; Orsenix: Other: Advisory board; ADC Therapeutics: Research Funding.
34
Sabadash, I. V. "PROBLEMS OF REVEALING CIRCUMSTANCES SUBJECTED TO ESTABLISHMENT WHEN INVESTIGATING CRIMES RELATED WITH NON-PAYMENT OF WAGES." Theory and Practice of Forensic Science and Criminalistics 17 (November 29, 2017): 121–27. http://dx.doi.org/10.32353/khrife.2017.14.
Full textAbstract:
In the paper we considered the features of organizing investigation of crimes related with non-payment of wages, namely a problem of revealing the circumstances subjected establishment. Having analyzed the proposed circumstances subjected to ascertainment during investigation of this category of crimes, let us generalize and distinguish, in our opinion, the most significant: 1. Existence of non-payment of wages to concrete employe- es/employee. 2. Availability of labor relations on the basis of an employment contract with enterprises, institutions, organizations of allforms of ownership and management, as well as with individual citizens. 3. Establishing of a period and amount of non-payment of wages. Determination of non-payment of wages is realized in following way: firstly, the total amount is established for the enterprise, institution, organization of all forms of ownership by periods, and then for a concrete employee. 4. Establishing of the fact of non-payment of wages by a concrete person - special subject alone or in accomplices. Obligatory feature of the subject of non-payment ofwages is the administrative-legal and functional statuses, which are ensured by the legality of the appointment or election of the head. 5. Determination of the method of non-payment ofwages. 6. Study of the causes ofwages non-payment occurrence. 7. Revealing the facts of using assets for other production needs, as well as the use of funds for unreasonable expenses and purposes not related with own economic activities. Consideration of the proposed list will allow to conduct the most complete and objective investigation of this type crimes, to obtain information relevantfor qualifying the actions of criminals, and to conduct timely and in a tactically correct manner investigative (search) actions, that in its turn, will positively affects the effectiveness and performance ofpre-trial investigation of crimes related with non-payment of wages.
35
Hughes, Mitchell E., Daniel J. Landsburg, Daniel J. Rubin, Stephen J. Schuster, Jakub Svoboda, Donald Edward Tsai, Kyle Robinson, et al. "Clinical Outcomes of Venetoclax Therapy in Patients with Relapsed/Refractory (r/r) Non Hodgkin Lymphomas (NHL)." Blood 132, Supplement 1 (November 29, 2018): 1706. http://dx.doi.org/10.1182/blood-2018-99-111194.
Full textAbstract:
Abstract Introduction: Venetoclax (VEN) is a highly effective agent for chronic lymphocytic leukemia (CLL) that targets BCL-2. Thus, it has been hypothesized to have efficacy in NHL and tested in phase-1/2 studies (Gerecitano JF, Blood 2015; de Vos S, Blood 2015; Davids MS, J Clin Oncol 2017). Overall response rates (ORR) observed in r/r NHL were 44% for all subtypes combined, 38% for follicular lymphoma (FL), 75% for mantle cell lymphoma (MCL), and 18% for diffuse large B-cell lymphoma (DLBCL). The adverse effect profile was consistent with the labeling despite dose escalation to doses higher than used in CLL. Additionally, VEN is a potential option in the r/r NHL setting, potentially providing less T cell toxicity compared to other agents used as bridging to T-cell therapies (Cummins NW, mBio, 2016; Dzhagalov I, J Immunol, 2008). We performed an analysis of all NHL patients (pts) treated with VEN at our institution to assess efficacy and safety of VEN in r/r NHL. Patients and Methods: We conducted a retrospective cohort study of all adult pts who received VEN for r/r NHL at the University of Pennsylvania between 4/2016 and 6/2018. Demographics, tumor lysis syndrome (TLS; events, prophylaxis and management), duration of therapy, reason for discontinuation, overall response, survival, and toxicities were examined. The primary endpoints were progression-free survival (PFS; defined as time from VEN start to disease progression or regimen change, death due to NHL or last-follow-up in remission), and overall survival using the Kaplan-Meier method. All other analyses were descriptive. Results: We identified 23 NHL pts for this analysis. NHL subtypes included DLBCL (35%; n=8), MCL (30%; n=7), Richter transformation (RT) (9%; n=2), transformed FL (tFL) (12%; n=4), post-transplant lymphoproliferative disease (PTLD) (4%; n=1), and marginal zone lymphoma (MZL; n=1) (4%). Median age at VEN start was 65 years; most pts were Ann Arbor stage IV (87%) and ECOG performance 2-4 (57%). NHL characteristics were MYC rearrangement (35%), BCL2 rearrangement (22%), double-hit lymphoma (26%), BCL2 IHC+ (22%), non-germinal center phenotype (13%). Median number of prior therapies was 4 (range: 2-13) with 17% having a prior autologous stem cell transplant. Median time to VEN initiation from prior therapy was 1 month (range, 0.5-9). Median VEN dose achieved was 400 mg (Range, 100-1200). Data for TLS are in Table 1. Median time on VEN was 2 months. While on VEN, 17% received radiation and 43% were on other anti-neoplastic therapy. Overall response rate (ORR) for the entire cohort was 26% (100% Partial Response [PR]). Subtypes with PR included MCL (13%), DLBCL (9%), and RT (4%). No PRs were observed with tFL, PTLD, nor MZL. Pts most commonly discontinued VEN for disease progression (74%); 2 pts (9%) remain on VEN therapy (range: 2-11 months). Median PFS and OS for the entire cohort were 2 months and 3 months, respectively, (Figure 1). Analyzed as histologic cohorts, large B-cell lymphomas (DLBCL, RT, PTLD, tFL) had similar median PFS and OS. However, small B-cell lymphomas (MCL, MZL) had median PFS and OS of 2.5 and 4 months, respectively. Two pts subsequently received CAR T-cell therapy post-VEN; one collected T-cells during VEN therapy and one collected T-cells prior to VEN start. Adverse events (AEs) occurred in approximately 65% while on VEN. AEs included: neutropenia (48%), thrombocytopenia (43%), TLS (30%), infection (26%), neutropenic fever (26%), and diarrhea (22%). One pt had an opportunistic infection (Pneumocystis jiroveci pneumonia) while on VEN and concurrent high-dose steroids. Conclusion: VEN monotherapy appears effective for NHL in phase I clinical trials. We describe our experience outside the setting of a clinical trial, including VEN used as part of multi-agent salvage therapy. Median PFS for our entire cohort is 2 months; AEs, while expected, were observed frequently, reflecting comorbidities. Clinical TLS events are attributed to pre-existing renal dysfunction (61% below 80 mL/min) during VEN escalation. The wide heterogeneity of VEN dose escalation, multi-agent combinations, and timing of initiation of VEN therapy are factors that require further investigation best designed as prospective clinical trials using other agents in combination with VEN. Disclosures Landsburg: Takeda: Consultancy; Curis: Consultancy, Research Funding. Schuster:Genentech: Honoraria, Research Funding; Novartis Pharmaceuticals Corporation: Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding; Nordic Nanovector: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees; Celgene: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding; Merck: Consultancy, Honoraria, Research Funding; OncLive: Honoraria; Gilead: Membership on an entity's Board of Directors or advisory committees; Dava Oncology: Consultancy, Honoraria; Pfizer: Membership on an entity's Board of Directors or advisory committees; Physician's Education Source, LLC: Honoraria. Svoboda:Pharmacyclics: Consultancy, Research Funding; Bristol-Myers Squibb: Consultancy, Research Funding; TG Therapeutics: Research Funding; Seattle Genetics: Consultancy, Research Funding; Regeneron: Research Funding; KITE: Consultancy; Kyowa: Consultancy; Merck: Research Funding. Gill:Novartis: Research Funding; Extellia: Consultancy, Membership on an entity's Board of Directors or advisory committees; Carisma Therapeutics: Equity Ownership. Mato:TG Therapeutics: Consultancy, Research Funding; AstraZeneca: Consultancy; Portola: Research Funding; Johnson & Johnson: Consultancy; Regeneron: Research Funding; Acerta: Research Funding; Celgene: Consultancy; Prime Oncology: Honoraria; Pharmacyclics, an AbbVie Company: Consultancy, Research Funding; AbbVie: Consultancy, Research Funding; Medscape: Honoraria. Altman:Epizyme: Other: payment to the institution to conduct clinical trial work; Incyte: Other: payment to the institution to conduct clinical trial work; Agios: Other: Payment to the institution to conduct the trial ; Pfizer: Other: payment to the institution to conduct clinical trial work; Ariad: Other: payment to the institution to conduct clinical trial work; BMS: Membership on an entity's Board of Directors or advisory committees; Astellas Pharma: Other; GSK: Other: payment to the institution to conduct clinical trial work; Boeringer Ingelheim: Other: payment to the institution to conduct clinical trial work; FujiFilm: Other: payment to the institution to conduct clinical trial work; Celgene: Membership on an entity's Board of Directors or advisory committees, Other: payment to the institution to conduct clinical trial work; Bayer: Other: payment to the institution to conduct clinical trial work; Celator: Other: payment to the institution to conduct clinical trial work; Cyclacel: Other: payment to the institution to conduct clinical trial work; Syros: Membership on an entity's Board of Directors or advisory committees; Novartis: Membership on an entity's Board of Directors or advisory committees; Genetech: Other: Payment to the institution to conduct clinical trial work; Janssen Pharmaceuticals: Membership on an entity's Board of Directors or advisory committees; Immune Pharmaceuticals: Membership on an entity's Board of Directors or advisory committees. Dwivedy Nasta:Pharmacyclics: Research Funding; Incyte: Research Funding; Roche: Research Funding; Aileron: Research Funding; Rafael/WF: Research Funding; Debiopharm: Research Funding; Merck: Other: DSMC; Takeda/Millenium: Research Funding; Celgene: Membership on an entity's Board of Directors or advisory committees.
36
He, Ruibo, Ting Ye, Jing Wang, Yan Zhang, Zhong Li, Yadong Niu, and Liang Zhang. "Medical Service Quality, Efficiency and Cost Control Effectiveness of Upgraded Case Payment in Rural China: A Retrospective Study." International Journal of Environmental Research and Public Health 15, no. 12 (December 13, 2018): 2839. http://dx.doi.org/10.3390/ijerph15122839.
Full textAbstract:
Background: As the principal means of reimbursing medical institutions, the effects of case payment still need to be evaluated due to special environments and short exploration periods, especially in rural China. Methods: Xi County was chosen as the intervention group, with 36,104, 48,316, and 59,087 inpatients from the years 2011 to 2013, respectively. Huaibin County acted as the control group, with 33,073, 48,122, and 51,325 inpatients, respectively, from the same period. The inpatients’ information was collected from local insurance agencies. After controlling for age, gender, institution level, season fixed effects, disease severity, and compensation type, the generalised additive models (GAMs) and difference-in-differences approach (DID) were used to measure the changing trends and policy net effects from two levels (the whole county level and each institution level) and three dimensions (cost, quality and efficiency). Results: At the whole-county level, the cost-related indicators of the intervention group showed downward trends compared to the control group. Total spending, reimbursement fee and out-of-pocket expense declined by ¥346.59 (p < 0.001), ¥105.39 (p < 0.001) and ¥241.2 (p < 0.001), respectively (the symbol ¥ represents Chinese yuan). Actual compensation ratio, length of stay, and readmission rates exhibited ascending trends, with increases of 7% (p < 0.001), 2.18 days (p < 0.001), and 1.5% (p < 0.001), respectively. The intervention group at county level hospital had greater length of stay reduction (¥792.97 p < 0.001) and readmission rate growth (3.3% p < 0.001) and lower reimbursement fee reduction (¥150.16 p < 0.001) and length of stay growth (1.24 days p < 0.001) than those at the township level. Conclusions: Upgraded case payment is more reasonable and suitable for rural areas than simple quota payment or cap payment. It has successfully curbed the growth of medical expenses, improved the efficiency of medical insurance fund utilisation, and alleviated patients’ economic burden of disease. However, no positive effects on service quality and efficiency were observed. The increase in readmission rate and potential hidden dangers for primary health care institutions should be given attention.
37
Andrianto, Agus. "Analisis Yuridis Penggunaan Perjanjian Pengikatan Jaminan Fidusia dan Kuasa (Ppjf) terhadap Mesin yang Masih dalam Pemesanan." JURNAL RECHTENS 8, no. 2 (December 31, 2019): 163–78. http://dx.doi.org/10.36835/rechtens.v8i2.532.
Full textAbstract:
Credit or financing based on sharia principles provided by banks carries risks, so in practice banks must pay attention to the principles of credit or financing based on sound Sharia Principles. As an intermediary institution and in line with the external and internal environment of the banking system, it is currently experiencing rapid development. Banks are required to be more flexible in providing financing / credit by accepting guarantees that will still exist in the future. One of them is through credit / financing activities based on sharia principles through instruments known in international trade transactions is a Letter of Credit ("L / C"). L / C is a guaranteed payment guarantee from the issuing Bank to make payment to the Exporter, for the presentation of the appropriate documents. For this reason, before opening an L / C, the issuing Bank must ensure that the customer / debtor has the ability to make payments when the customer's obligations have matured. Keywords : Credit , Bank, Letter of Credit
38
Pratz, Keith W., Mohamad Cherry, Jessica K. Altman, Brenda Cooper, Jose Carlos Cruz, Joseph G. Jurcic, Mark J. Levis, et al. "Updated Results from a Phase 1 Study of Gilteritinib in Combination with Induction and Consolidation Chemotherapy in Subjects with Newly Diagnosed Acute Myeloid Leukemia (AML)." Blood 132, Supplement 1 (November 29, 2018): 564. http://dx.doi.org/10.1182/blood-2018-99-110975.
Full textAbstract:
Abstract Introduction: Gilteritinib is a novel, potent, highly-selective oral fms-like tyrosine kinase 3 (FLT3)/AXL inhibitor. Once-daily single-agent gilteritinib doses of ≥80 mg/day elicited antileukemic responses in FLT3 mutation-positive (FLT3mut+) subjects with relapsed/refractory AML (Perl AE, et al. Lancet Oncol. 2017). We examined the safety/tolerability and antitumor activity of gilteritinib plus front-line intensive chemotherapy in newly diagnosed AML patients. Methods: This ongoing open-label, dose-escalation/expansion phase 1 study (NCT02236013) assesses the safety/tolerability and antitumor effects of gilteritinib combined with 7+3 induction and high-dose cytarabine consolidation, and as single-agent maintenance therapy in subjects aged ≥18 years with newly diagnosed AML (excluding core-binding factor translocations). Dose escalation followed a 3+3 design; successive cohorts of 3-6 subjects received 40, 80, 120, or 200 mg/day gilteritinib. Subjects received ≤2 cycles of a 7+3 induction regimen (cytarabine 100 mg/m2/day, Days 1-7 plus idarubicin 12 mg/m2/day, Days 1-3 [dose-escalation and dose-expansion cohorts], and once-daily gilteritinib on Days 4-17 [Schedule 1]). After completion of the dose-expansion cohort using Schedule 1, a new cohort of patients were enrolled. In this cohort of six patients, gilteritinib administration was changed to Days 8-21 (Schedule 2) in preparation for phase 3 studies and daunorubicin 90 mg/m2/day, administered on Days 1-3, was used as an alternative anthracycline to idarubicin. During consolidation, subjects received cytarabine (1.5 g/m2 every 12 hours, Days 1, 3, and 5) and once-daily gilteritinib (Days 1-14) at the induction dose for ≤3 cycles. Subjects in the dose-expansion cohort received gilteritinib at the recommended expansion dose established during dose escalation. Transplantation was allowed for responding subjects. After consolidation or transplantation with stable engraftment, subjects received maintenance therapy with once-daily gilteritinib (28-day cycles; ≤26 cycles). Results: As of July 2, 2018, 62 subjects have been enrolled; 60 are included in the safety analysis set. Most subjects were male (66.7%; median age, 59.5 years [range, 23-77]) and 32 (53.3%) had FLT3 mutations (FLT3-ITD, n=23). During dose-escalation, two subjects in the 40 mg/day cohort who had received gilteritinib on Days 1-14 experienced dose-limiting toxicities (DLTs; neutropenia, thrombocytopenia, decreased ejection fraction). After the gilteritinib induction schedule change, no more DLTs occurred at this dose. Two subjects in the 200 mg/day cohort experienced DLTs (neutropenia, neutropenic enterocolitis). The maximum tolerated dose and the recommended expansion dose were established at 120 mg/day. Grade ≥3 adverse events (AEs) in ≥10% of patients were febrile neutropenia (63.3%), thrombocytopenia (18.3%), decreased platelet count (16.7%), neutropenia (15.0%), bacteremia (10.0%), sepsis (10.0%), and decreased white blood cell count (10.0%). Serious drug-related AEs in >1 subject were febrile neutropenia (n=9), small intestinal obstruction, lung infection, sepsis, and decreased ejection fraction (all n=2). The end-of-treatment investigator-reported rate of composite complete remission (CRc) for response evaluable FLT3mut+ subjects receiving gilteritinib 120 mg on Schedule 1 (n=17) was 100%. The CRc rate in FLT3mut+ subjects receiving Schedule 2 induction with daunorubicin was also 100% (Table). Enrollment in the Schedule 2 cohort receiving idarubicin is ongoing; the two subjects in this cohort have not been assessed for response. Among subjects who received ≥80 mg/day gilteritinib (n=47), CRc rates for FLT3mut+ subjects were 88.9% (n=24/27). Median overall survival has not been reached. Median disease-free survival was 297 days (95% CI: 112, not reached). Assessment of minimum residual disease in FLT3-ITD patients using a next-generation sequencing-based assay is ongoing; results will be available at the time of presentation. Conclusions: Gilteritinib can be safely combined with intensive chemotherapy, and given as single-agent maintenance therapy in subjects with newly diagnosed AML. Treatment was well tolerated. High response rates were observed in FLT3mut+ subjects after treatment with either idarubicin or daunorubicin in combination with two different gilteritinib administration schedules. Disclosures Pratz: Millenium/Takeda: Research Funding; AbbVie: Consultancy, Research Funding; Agios: Research Funding; Astellas: Consultancy, Research Funding; Boston Scientific: Consultancy. Altman:Astellas Pharma: Other; Agios: Other: Payment to the institution to conduct the trial ; Epizyme: Other: payment to the institution to conduct clinical trial work; BMS: Membership on an entity's Board of Directors or advisory committees; Novartis: Membership on an entity's Board of Directors or advisory committees; Pfizer: Other: payment to the institution to conduct clinical trial work; Cyclacel: Other: payment to the institution to conduct clinical trial work; Celator: Other: payment to the institution to conduct clinical trial work; Ariad: Other: payment to the institution to conduct clinical trial work; Bayer: Other: payment to the institution to conduct clinical trial work; Genetech: Other: Payment to the institution to conduct clinical trial work; FujiFilm: Other: payment to the institution to conduct clinical trial work; Incyte: Other: payment to the institution to conduct clinical trial work; Celgene: Membership on an entity's Board of Directors or advisory committees, Other: payment to the institution to conduct clinical trial work; Boeringer Ingelheim: Other: payment to the institution to conduct clinical trial work; Syros: Membership on an entity's Board of Directors or advisory committees; GSK: Other: payment to the institution to conduct clinical trial work; Janssen Pharmaceuticals: Membership on an entity's Board of Directors or advisory committees; Immune Pharmaceuticals: Membership on an entity's Board of Directors or advisory committees. Cruz:Takeda: Speakers Bureau. Jurcic:Kura Oncology: Research Funding; Forma Therapeutics: Research Funding; Celgene: Research Funding; Daiichi-Sankyo: Research Funding; Incyte: Consultancy; Actinium Pharmaceuticals, Inc: Research Funding; Novartis: Membership on an entity's Board of Directors or advisory committees; Syros Pharmaceuticals: Research Funding; Genetech: Research Funding; AbbVie: Consultancy, Research Funding; Astellas: Research Funding. Lin:Jazz Pharmaceuticals: Honoraria. Perl:AbbVie: Membership on an entity's Board of Directors or advisory committees; Actinium Pharmaceuticals: Membership on an entity's Board of Directors or advisory committees; Daiichi Sankyo: Consultancy; Novartis: Membership on an entity's Board of Directors or advisory committees; Pfizer: Membership on an entity's Board of Directors or advisory committees; Arog: Consultancy; NewLink Genetics: Membership on an entity's Board of Directors or advisory committees; Astellas: Consultancy. Podoltsev:Pfizer: Membership on an entity's Board of Directors or advisory committees; Astellas Pharma: Research Funding; LAM Therapeutics: Research Funding; Astex Pharmaceuticals: Research Funding; Genentech: Research Funding; Boehringer Ingelheim: Research Funding; Sunesis Pharmaceuticals: Research Funding; Daiichi Snakyo: Research Funding; Celator: Research Funding; Celgene: Research Funding; Pfizer: Research Funding. Schiller:bluebird bio: Research Funding; Astellas Pharma: Membership on an entity's Board of Directors or advisory committees, Research Funding. Liu:Astellas Pharma: Employment. Bahceci:Astellas Pharma: Employment.
39
Lutfi, Abdalwali, Manaf Al-Okaily, Malek Hamed Alshirah, Ahmad Farhan Alshira’h, Thaer Ahmad Abutaber, and Manal Ali Almarashdah. "Digital Financial Inclusion Sustainability in Jordanian Context." Sustainability 13, no. 11 (June 2, 2021): 6312. http://dx.doi.org/10.3390/su13116312.
Full textAbstract:
Digital Financial Inclusion (DFI) refers to efforts to make digital financial services available and affordable to all individuals and institutions, regardless of their net expense or institution size and demographic location. Despite the immense benefits of DFI and DFI-based products and services such as mobile money and payment systems, users’ acceptance is thin, limited, and disappointing in some developing countries as Jordan. Consequently, this study has investigated the factors influencing the acceptance of the mobile payment system in the Jordanian context. This study’s research model synthesizes the Technology Acceptance Model (TAM) variables and extended the model with perceived financial cost as an independent variable. The research model has been empirically confirmed by fitting the model to data collected from 304 Jordanian citizens using a survey instrument. The data were analysed using Partial Least Squares-Structural Equation Modelling (PLS-SEM). The result has confirmed that behavioural intention to use the m-payment system is significantly and positively influenced by perceived usefulness and perceived financial cost; behavioural intention to use m-payment system was not found to be significantly and positively influenced by perceived ease of use and hence the related hypothesis was not supported. Finally, conclusions and recommendations are further discussed in the last section of this paper.
40
Boranukov, Aleksandr M. "On Qualifying Crimes Committed with Electronic Means of Payment." Ugolovnaya yustitsiya, no. 16 (2020): 7–9. http://dx.doi.org/10.17223/23088451/16/2.
Full textAbstract:
Crimes committed with electronic means of payment undermine the financial system stability and economic security of the state. The preliminary investigation bodies may qualify unlawful mercenary taking and conversion of another person’s property using an electronic means of payment, including a debit or credit card, as fraud or theft depending on the criterion of secrecy. Larceny of the payment instrument must be regarded as preparation, attempted or completed crime depending on the possibility to manage the victim’s bank account and its implementation, since the sums of money are placed (stored) in a credit institution until they are disposed (spent).
41
Khomenko, E. G. "Modern technologies in the national payment system and state security: combination rules." Courier of Kutafin Moscow State Law University (MSAL)), no. 9 (November 7, 2020): 162–70. http://dx.doi.org/10.17803/2311-5998.2020.73.9.162-170.
Full textAbstract:
The national payment system, which provides services to the entire spectrum of the financial system using all the latest technologies, is a complex institution that is important for the state and society as a whole. Modern technologies significantly simplify the life of the population and speed up the process of providing payment services. Domestic information technologies are developed and used in the provision of payment services, some of which are discussed in this article. Also studied the correlation of business interests and state interests underlying the development of the national payment system as a component of the Russian financial system, able to ensure the financial security of the country and guarantee her economic sovereignty under conditions of globalization and integration of Russia into the world economic system.
42
GRETCHENKO, Anatoliy Ivanovich, Olga Gennadevna DEMENKO, and Alexander Anatolievich GRETCHENKO. "Model of Remuneration: ‘Catching up’ Type (Russian Case)." Journal of Advanced Research in Law and Economics 9, no. 4 (June 30, 2018): 1249. http://dx.doi.org/10.14505//jarle.v9.4(34).10.
Full textAbstract:
Purpose: the aim of our research is the development of the theory and methodology of wages from the position of institutional and complementary approaches which encourage formation and implementation of the compensation model of payment at the corporate level, in the background of which the market price of labor lies, which is determined in the process of interaction of employment relations actors.
Design/methodology/approach: this paper is based on the description and analysis of payment in Russia
Findings: based on the empirical analysis of Russian and foreign literature, the author showed a trend of ‘catching up’ development wages model in Russian’s organizations. The author introduced scientifically based historical allocation of payment model development in Russia and suggested their classification. The conceptual framework of payment institution has been expanded. The conceptual approaches to forming the compensation model of payment at the corporate level have been reasoned. The mechanism of development and implementation of the compensation model of payment at the corporate level has been proposed. It has been proved that the contents of the ‘grading’ process using Western methods of job evaluation is identical to the content of the ‘tariff regulation’ and represents the reducing of labor at the corporate level. Author's definition of a social package has been justified.
Originality/value: the paper discusses and develops conceptual frameworks, theoretical and methodological approaches to payment in Russia in the context of lessons derived from developed countries, as well as the guidelines to improve the mechanism of remuneration at the corporate level with regard to the economic conditions of modernization; the author considers that scientific findings will be of value for companies and their corporate governance.
43
Yas’kova, Natal’ya Yur’evna, and Tat’yana Romanovna Alekseeva. "Development of institutional bases of leasing." Vestnik MGSU, no. 2 (February 2016): 146–58. http://dx.doi.org/10.22227/1997-0935.2016.2.146-158.
Full textAbstract:
Institutional approach to the research of leasing in modern conditions is considered in the article. Formal and informal institutions of the leasing relations are investigated. Ratios of public and subjective expenses and benefits in institutional system of leasing are shown. Features of interaction of agents of the leasing relations, their interests and tendency to manifestation of opportunistic behavior are investigated. The typology of mechanisms of implementation of institutional changes is considered. The need of structural changes of the institutes of leasing relations is proved. It is offered to introduce “institution of engineering” in the structure of institutions of leasing relations. It will allow providing harmonization of the interests of the agents of leasing relations, decreasing their opportunistic behavior, and reducing the transactional expenses of the participants of leasing. It will promote prevention of their opportunistic behavior and reduction of transaction expenses of the participants of leasing. In our opinion, “the institution of leasing” is a set of formal and informal rules, norms and mechanisms of enforcement of their performance (institutes of property, financial rent (leasing), crediting, insurance and other institutes of leasing relations), which govern the property and economic relations, the arising relations with acquisition of ownership and its subsequent assignment for use for a certain time with payment. These norms and rules are necessary for ensuring stability and definiteness in the relations between the participants of leasing, and also for protection of their rights and economic interests.
44
Tannuri-Pianto, Maria. "Contagion in the Brazilian interbank currency exchange market: an empirical analysis." Estudos Econômicos (São Paulo) 36, no. 2 (June 2006): 251–62. http://dx.doi.org/10.1590/s0101-41612006000200003.
Full textAbstract:
The risk of contagion is the possibility that the failure of a financial institution affected by an exogenous shock generates the failure of other institutions not initially affected by the shock. As pointed out by Upper and Worms (2002) and others, the domino effect in the payment system depends on the precise pattern of interbank linkages. This paper studies the occurrence of financial contagion after the exogenous failure of an institution authorized to operate in the Brazilian interbank currency market. The data contain information about all the actual transactions that occurred in this market from August 1st, 2000 to October 31st, 2002. The adopted methodology shows the occurrence of contagion propagation in several subsequent rounds after the initial failure. We quantify the number of institutions that breakdown and the financial losses of the market. There is a large increase in the number of failed institutions during the period of the presidential elections in 2002.
45
Hamja, Hamja. "PERAN BANK INDONESIA DALAM KEJAHATAN PERBANKAN YANG DILAKUKAN OLEH BANK BALI." Yustitia 4, no. 2 (October 22, 2018): 162–77. http://dx.doi.org/10.31943/yustitia.v4i2.42.
Full textAbstract:
The existence of a central bank is also needed to regulate and supervise banks so that their activities can develop healthy and run smoothly so that it can encourage economic activities. This is considering that the existence of an impartial regulator will bring banks to carry out their operations efficiently and be able to advance economic development. In the interbank payment system, Bank Indonesia has the duty to regulate and maintain a smooth payment system. Including the problems that occurred in the case of Bank Bali, the task of Bank Indonesia as an institution that regulates and maintains a smooth payment system between BDNI and Bank Bali.
46
Ferrada, Paula, David Evans, Sara Parker, Sammy Pedram, and Curtis N. Sessler. "4107 Limited Echocardiogram Examinations Performed by Intensivists: A Surgeon-Driven Multidisciplinary Program." American Surgeon 83, no. 1 (January 2017): 78–81. http://dx.doi.org/10.1177/000313481708300129.
Full textAbstract:
Limited transthoracic echocardiogram (LTTE) has been introduced as a tool to direct resuscitation. At our institution, a multidisciplinary training program was instituted. Our hypothesis is that in spite all efforts for multidisciplinary training, certification, and credentialing, limited echocardiograms are under billed for. A training program was implemented in August 2010. This was followed by a process of credentialing and adding LTTE to the billing privileges for providers. Institutional Review Board approval was obtained to review all the studies performed from August 2010 to October 2014. About 4107 LTTEs were performed during the study period. Only 685 examinations were billed for (16.6%). The total amount billed for all the studies was $80,819.00. The number of studies billed for and performed in the emergency department (ED) were 342, and 343 studies were billed while performed in the intensive care unit (ICU). Our institution received payment at a higher rate when the studies were performed in the ICU (71.7%) versus ED (49.4%), P < 0.0001. The total actual reimbursement for the ED was $6487.29 and for the ICU was $8213.95 for a total of $14,701.24. The mean reimbursement amount was $35.59. If all of the studies were billed for and reimbursed at the average payment amount, the institution would have received $146,168.13. A multidisciplinary approach is pivotal for the success of intensivist-driven bedside echocardiogram programs. Education regarding credentialing and billing is a necessary addition to ensure sustainability of such efforts.
47
Mawarrini, Robertta Indira. "Identifikasi Pembayaran Bergerak (Mobile Payment) yang Mengganggu (Disruptive) di Indonesia." Perisai : Islamic Banking and Finance Journal 1, no. 3 (December 28, 2017): 215. http://dx.doi.org/10.21070/perisai.v1i3.1179.
Full textAbstract:
This research aims to identify disruptive mobile payment in Indonesia. Mobile payment as a sector of financial technology is enabling the lifestyle transformation of electronic banking. The future of retail banking is a smartphone experience that gladden and customers also aspire for a “bank in my pocket”. Mobile payment as the second sector most likely to be disrupted in the intersection of finance and technology industry. The promising approach of disruptive innovations is proposed by Professor Christensen from Harvard Bussiness School. They suggest that two strategies for identifying the new disruptive growth of business, as following: “creating a new market as a base of disruption” and “disrupting the business model from the low end”. Our research findings that mobile payment tends to replicate bank’s business model, its business model only espouse financial institution. Customers also desire their mobile payment have to the following three priorities: anytime and anywhere, fully digital (convenience), fast and accurate. When epicenter of disruption of mobile payment have been widely misunderstood and its basic principle frequently misapplied. Islamic mobile payment should be immediately developed in order to expand the coverage of Islamic financial services
48
Halberda, Jan. "Nienależne świadczenie w polskim Kodeksie zobowiązań z 1933 r. na tle porównawczym." Krakowskie Studia z Historii Państwa i Prawa 9, no. 1 (2016): 67–95. http://dx.doi.org/10.4467/20844131ks.16.004.5076.
Full textAbstract:
Undue Payment in the Polish Code of Obligations of 1933 as Compared with Other Regulations of That Time The present paper discusses the concept of undue payment as found in the Polish Code of Obligations of 1933. The research is comparative in nature since it also explores the institution in question in other contemporary codes (Code Civil, ABGB, BGB and Obligationrecht), Roman law, and the Polish Civil Code of 1964 (1). The discussion is concerned with the framework of legal provisions on undue payment in the aforementioned sources (2). Furthermore, while applying a framework of the Roman condictiones the paper analyses the grounds of the action (3). It presents circumstances which allowed a payor to seek recovery of his payment (4–6) and those which precluded the claim (7). Then the paper gives an illustration of the scope of a payee’s liability (8). In his fi nal remarks, the author attempts to assess undue payment as regulated in the Code of Obligations (9).
49
Fleischman, Tomaž, and Paolo Dini. "Mathematical Foundations for Balancing the Payment System in the Trade Credit Market." Journal of Risk and Financial Management 14, no. 9 (September 21, 2021): 452. http://dx.doi.org/10.3390/jrfm14090452.
Full textAbstract:
The increasingly complex economic and financial environment in which we live makes the management of liquidity in payment systems and the economy in general a persistent challenge. New technologies make it possible to address this challenge through alternative solutions that complement and strengthen existing payment systems. For example, interbank balancing and clearing methods (such as real-time gross settlement) can also be applied to private payments, complementary currencies, and trade credit clearing to provide better liquidity and risk management. The paper defines the concept of a balanced payment system mathematically and demonstrates the effects of balancing on a few small examples. It then derives the construction of a balanced payment subsystem that can be settled in full and therefore that can be removed in toto to achieve debt reduction and payment gridlock resolution. Using well-known results from graph theory, the main output of the paper is the proof—for the general formulation of a payment system with an arbitrary number of liquidity sources—that the amount of liquidity saved is maximum, along with a detailed discussion of the practical steps that a lending institution can take to provide different levels of service subject to the constraints of available liquidity and its own cap on total overdraft exposure. From an applied mathematics point of view, the original contribution of the paper is two-fold: (1) the introduction of a liquidity node with a store of value function in obligation-clearing; and (2) the demonstration that the case with one or more liquidity sources can be solved with the same mathematical machinery that is used for obligation-clearing without liquidity. The clearing and balancing methods presented are based on the experience of a specific application (Tetris Core Technologies), whose wider adoption in the trade credit market could contribute to the financial stability of the whole economy and a better management of liquidity and risk overall.
50
Levis, Mark J., Alexander E. Perl, Jessica K. Altman, Jorge E. Cortes, Catherine C. Smith, Maria R. Baer, David F. Claxton, et al. "Impact of Minimal Residual Disease and Achievement of Complete Remission/Complete Remission with Partial Hematologic Recovery (CR/CRh) on Overall Survival Following Treatment with Gilteritinib in Patients with Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) with FLT3 Mutations." Blood 132, Supplement 1 (November 29, 2018): 1458. http://dx.doi.org/10.1182/blood-2018-99-110971.
Full textAbstract:
Abstract Background: Gilteritinib, a highly selective fms-like tyrosine kinase 3 (FLT3)/AXL inhibitor, demonstrated strong antileukemic activity at doses ≥80 mg/day in patients with R/R AML with FLT3 mutations (FLT3mut+) enrolled in the CHRYSALIS phase 1/2 study (NCT02014558). We analyzed the impact of minimal residual disease (MRD) and achievement of complete remission/complete remission with partial hematologic recovery (CR/CRh) on overall survival (OS) in patients with FLT3mut+ R/R AML from the CHRYSALIS study. Methods: Minimal residual disease was assessed by next-generation sequencing (NGS) using an Illumina® sequencing platform that quantified FLT3-ITD and total FLT3 alleles in a subgroup of FLT3mut+ patients with internal tandem duplication (ITD) mutations across all gilteritinib doses who had bone marrow samples available at baseline and at ≥1 post-baseline time point. The ITD variant allele frequency (VAF) was the FLT3-ITD to total FLT3 ratio. An ITD VAF ≤10−4 defined MRD-negative status. For FLT3 VAF, a capture-based NGS assay that included all exons of FLT3 was used. Sample DNA was used to generate whole genome libraries which were hybridized with a custom probe to capture target fragments that were sequenced on an Illumina® MiSeq platform. Treatment response was evaluated according to the CR/CRh rate. Complete remission was assessed according to the 2003 modified International Working Group criteria and CRh was defined as absolute neutrophil count >0.5 × 109/L and platelet count >50 × 109/L. The rate of CR/CRh has been used as an approval endpoint for R/R AML. Results: The demographic and baseline characteristics of patients who were assessed for MRD and CR/CRh were representative of the entire CHRYSALIS R/R AML population. A total of 108 FLT3-ITDmut+ patients were analyzed for MRD; 95 of these patients had received ≥80 mg/day gilteritinib, which was shown to induce maximum FLT3 inhibition and antileukemic response. Eighty-two of the 95 patients were MRD-positive and 13 achieved MRD-negative status at any post-baseline time point. Of these 95 patients, 49 had a best overall response of composite complete remission (CRc; ie, CR plus CR with incomplete hematologic plus CR with incomplete platelet recovery) and 11 were MRD-negative. None of the patients who received <80 mg/day gilteritinib achieved MRD-negative status. Of the 46 patients who did not achieve CRc, two were MRD-negative. As seen in Figure 1, patients who had achieved CRc and were MRD-negative (n=11) had longer median OS (168.7 weeks; 95% CI: 41.7, not reached) than those who had achieved CRc and were MRD-positive (n=38; 36.1 weeks; 95% CI: 27.1, 51.7; P=.004). Excluding patients with an OS duration less than the median time to reach MRD-negative status, MRD-negative patients (n=12) had a median OS of 131.4 weeks (95% CI: 35.1, not reached) compared with MRD-positive patients (n=38) who had a median OS of 47.3 weeks (95% CI: 42.7, 61.1). Of the 95 patients who received ≥80 mg/day gilteritinib in the MRD analysis, 24 had a best overall response of CR/CRh. Of the 24 patients with CR/CRh, 10 (41.67%) were MRD-negative. Of the 71 patients without CR/CRh, three (4.2%) were MRD-negative. Patients who received 120 mg/day gilteritinib were previously shown to have longer survival than patients in other dose cohorts. Of the 56 patients who received 120 mg/day gilteritinib, 13 achieved a best overall response of CR/CRh. As shown in Figure 2, patients who achieved CR/CRh had a median OS of 70.6 weeks (95% CI: 27.1, not reached) and a 52-week survival probability of 66.7% (95% CI: 33.7, 86.0) compared with patients who did not achieve CR/CRh who had a median OS of 32.4 weeks (95% CI: 16.0, 40.9) and a 52-week survival probability of 20.2% (95% CI: 9.5, 33.6). Conclusions: Single-agent therapy with gilteritinib induced deep molecular responses, including MRD negativity, in heavily pretreatedpatients with FLT3-ITDmut+ R/R AML. Our results suggest a potential association between MRD-negative status and longer survival in patients withFLT3-ITDmut+ R/R AML. Additionally, patients who achieved CR/CRh appear to have both a higher rate of MRD negativity and longer OS than patients who did not achieve CR/CRh. Disclosures Perl: Daiichi Sankyo: Consultancy; Astellas: Consultancy; NewLink Genetics: Membership on an entity's Board of Directors or advisory committees; Pfizer: Membership on an entity's Board of Directors or advisory committees; Novartis: Membership on an entity's Board of Directors or advisory committees; Actinium Pharmaceuticals: Membership on an entity's Board of Directors or advisory committees; Arog: Consultancy; AbbVie: Membership on an entity's Board of Directors or advisory committees. Altman:Syros: Membership on an entity's Board of Directors or advisory committees; Celgene: Membership on an entity's Board of Directors or advisory committees, Other: payment to the institution to conduct clinical trial work; Janssen Pharmaceuticals: Membership on an entity's Board of Directors or advisory committees; GSK: Other: payment to the institution to conduct clinical trial work; FujiFilm: Other: payment to the institution to conduct clinical trial work; Pfizer: Other: payment to the institution to conduct clinical trial work; Cyclacel: Other: payment to the institution to conduct clinical trial work; Incyte: Other: payment to the institution to conduct clinical trial work; Genetech: Other: Payment to the institution to conduct clinical trial work; Ariad: Other: payment to the institution to conduct clinical trial work; Bayer: Other: payment to the institution to conduct clinical trial work; BMS: Membership on an entity's Board of Directors or advisory committees; Novartis: Membership on an entity's Board of Directors or advisory committees; Epizyme: Other: payment to the institution to conduct clinical trial work; Celator: Other: payment to the institution to conduct clinical trial work; Agios: Other: Payment to the institution to conduct the trial ; Astellas Pharma: Other; Immune Pharmaceuticals: Membership on an entity's Board of Directors or advisory committees; Boeringer Ingelheim: Other: payment to the institution to conduct clinical trial work. Cortes:Novartis: Consultancy, Research Funding; Astellas Pharma: Consultancy, Research Funding; Pfizer: Consultancy, Research Funding; Daiichi Sankyo: Consultancy, Research Funding; Arog: Research Funding. Smith:Astellas Pharma: Research Funding. Jurcic:Daiichi-Sankyo: Research Funding; Actinium Pharmaceuticals, Inc: Research Funding; Forma Therapeutics: Research Funding; Astellas: Research Funding; Genetech: Research Funding; Incyte: Consultancy; Syros Pharmaceuticals: Research Funding; Celgene: Research Funding; AbbVie: Consultancy, Research Funding; Kura Oncology: Research Funding; Novartis: Membership on an entity's Board of Directors or advisory committees. Ritchie:Incyte: Consultancy, Speakers Bureau; Bristol-Myers Squibb: Research Funding; NS Pharma: Research Funding; ARIAD Pharmaceuticals: Speakers Bureau; Astellas Pharma: Research Funding; Novartis: Consultancy, Other: Travel, Accommodations, Expenses, Research Funding, Speakers Bureau; Pfizer: Consultancy, Research Funding; Celgene: Consultancy, Other: Travel, Accommodations, Expenses, Speakers Bureau. Strickland:Novartis: Consultancy, Membership on an entity's Board of Directors or advisory committees; Boehringer Ingelheim: Consultancy, Membership on an entity's Board of Directors or advisory committees, Research Funding; Astellas Pharma: Consultancy; Pfizer: Consultancy, Membership on an entity's Board of Directors or advisory committees; Baxalta: Consultancy, Membership on an entity's Board of Directors or advisory committees; CTI Biopharma: Consultancy, Membership on an entity's Board of Directors or advisory committees; Tolero Pharmaceuticals: Consultancy, Membership on an entity's Board of Directors or advisory committees; Sunesis Pharmaceuticals: Consultancy, Research Funding. Hill:Ligacept, LLC: Other: Shareholder. Rosales:Astellas Pharma: Employment. Bahceci:Astellas Pharma: Employment.